The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.

On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]

Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."



Personnes-ressources

Partner
Associée principale

Publications récentes

Abonnez-vous et restez à l’affût des nouvelles juridiques, informations et événements les plus récents...